https://www.predictmedix.com/post/predictmedix-is-partnering-with-mcgill-researchers-for-clinical-research TORONTO, ON / ACCESSWIRE / November 10, 2020 / Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) ("Predictmedix" or the "Company") is pleased to announce that the company is partnering with the research group led by Dr. Samira Rahimi for clinical research. Professor Rahimi is an Assistant Professor in McGill University's Department of Family Medicine, associate member of McGill's Electrical and Computer Engineering Department, and affiliated scientist at the Lady Davis Institute for Medical Research of Jewish General Hospital.
Predictmedix will be working with Dr. Rahimi's research group for its three industry verticals which include screening for infectious disease associated symptoms, screening for cannabis/alcohol impairment along with mental health screening technologies which are being developed by the company.
"We are extremely excited with the partnership with Dr. Samira Rahimi's team. Dr. Rahimi is one of the most recognized AI - healthcare scientists in Canada and we look forward to with her and her research team for our 3 major verticals.", said Dr. Rahul Kushwah, COO of Predictmedix Inc.
Speaking of the partnership, Dr. Rahimi commented, "My team and I are looking forward to working with Predictmedix team. Predictmedix is one of the young and leading AI companies which aims to improve our healthcare system through innovative and cutting-edge digital health technologies."
Biography of Dr. Samira Rahimi:
Samira Rahimi Eng. Ph.D. is an Assistant Professor in the Department of Family Medicine at McGill University, and affiliated scientist at Lady Davis Institute for Medical Research of the Jewish General Hospital. She is FRQS Junior 1 Research Scholar, and regular member of Institute of Electrical and Electronics Engineers (IEEE), Association for the Advancement of Artificial Intelligence (AAAI), OBVIA, CIRRELT-IVADO, Cardiometabolic Health Diabetes and Obesity research network (CMDO), Canadian Consortium on Neurodegeneration in Aging (CCNA) and society officer of Canadian Operational Research Society.
She completed her postdoctoral training at Family and Emergency Medicine Department of Universit Laval, and her doctorate studies (in Industrial and System Engineering with a focus on health care systems) at Mechanical Engineering Department of Universit Laval. She is the recipient of numerous scholarships, fellowships, and awards among them the 2015 Canada Women in Engineering award of IEEE.
With an interdisciplinary background, she is interested in the development, evaluation, and implementation of clinical decision support tools and patient decision aids, as well as integrating human-centered AI tools in primary health care.
Her work as Principal Investigator has been funded by the Fonds de recherche du Qubec - Sant (FRQS), Natural Sciences and Engineering Research Council (NSERC), Roche Canada, Brocher Foundation (Switzerland), and the Strategy for Patient-Oriented Research (SPOR)-Canadian Institutes of Health Research (CIHR).
About Predictmedix Inc.
Predictmedix Inc. is an artificial intelligence ("AI") company developing disruptive tools for impairment testing and healthcare. It is intended that the Company's cannabis and alcohol impairment detection tools will be used across various workplaces and by law enforcement agents. Its technology uses facial and voice recognition to identify both cannabis and alcohol impairment by utilizing multiple features along with numerous different data points. Testing does not require any body fluids or human intervention, thereby helping to remove human error and the potential for discrimination and prejudice.
The Company is also developing AI based screening for the healthcare industry. The recent advent of COVID-19 pandemic has placed unprecedented stress on the global economy and highlights the need for tools to help screen mass populations for infectious diseases, with the hope of preventing pandemics in the future. In turn, Predictmedix Inc. is expanding its proprietary AI technology to screen for infectious disease symptoms.
Additionally, psychiatric disorders such as depression, dementia and Alzheimer's disease can carry a significant burden and early identification is the key to better management. To help address this, the Company is also expanding its proprietary AI technology to screen for psychiatric and/or brain disorders such as depression, dementia and Alzheimer's disease. To find out more visit us at www.predictmedix.com
Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time."
For further information, please contact: Dr. Rahul Kushwah, Chief Operating Officer Tel: 647 889-6916 Email: rahul@predictmedix.com